Welcome to Reason Foundation’s newsletter on psychedelics policy. This edition covers:
- How Congress can promote access to psychedelic medicine
- New data dashboard and analysis for rescheduling psychedelics
- The state roundup
Legislative approaches that could improve access to psychedelic-based medicine
Reason Foundation responded to a request for comment from the Congressional Psychedelics Advancing Therapies Caucus. We recommended that Congress should reform the need for psychedelic pharmaceutical companies to prove “efficacy“ before trial participants are able to purchase treatment, expand the use of observational data in drug approvals, and explore how novel psychedelic treatments could make government healthcare more cost-efficient. Read about these recommendations and more here.
Reason Foundation has produced additional commentaries addressing psychedelics reform proposals in Nevada, Arizona, and Washington.
Exploring new data on the safety of psychedelics
The new leaders of Health and Human Services (HHS) may consider rescheduling certain psychedelics currently listed under Schedule I of the Controlled Substances Act in collaboration with other federal agencies. We have compiled an extensive list of public health data related to psychedelics in a new dashboard and written commentary detailing how this data can help the new administration evaluate the safety of psychedelics.
State roundup
Dozens of state legislative proposals related to psychedelics have been filed across America. Proposals include everything from authorizing facilitated access to psilocybin services within a clinical setting to decriminalization of the personal possession of psychedelics. Our state roundup offers an exhaustive list of bills that have been introduced or have made progress in the last two months.
Sign up for the Psychedelics Policy Newsletter